Basic Information
VELETRI POWDER FOR SOLUTION FOR INFUSION 0.5MG/VIAL
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN15405P
January 11, 2018
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 4, 2025
XB01AC09
Company Information
JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD
JOHNSON & JOHNSON INTERNATIONAL (SINGAPORE) PTE LTD
Active Ingredients
Strength: 0.5mg
Detailed Information
Contraindications
**4.3 Contraindications** Veletri® is contraindicated in patients: - with known hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. - with congestive heart failure arising from severe left ventricular dysfunction. - Veletri® must not be used chronically in patients who develop pulmonary oedema during dose-ranging.
Indication Information
**4.1 Therapeutic indications** Veletri® is indicated for: Pulmonary Arterial Hypertension. Veletri® is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO Functional Class III–IV symptoms to improve exercise capacity (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).